In a new note to investors today, an analyst has provided a rating update for the Healthcare company, Liberty Health Sciences Inc (LHS). Analyst Noel Atkinson from Clarus remains bullish on the stock and has a C$1.75 price target.
Atkinson said:
“We expect first dried flower sales in Florida by late summer 2019. Flower remains a highly sought-after means of consuming medical cannabis across North America, so we expect patient registration growth to accelerate once the state adds flower to the product list. Average retail price per gram-equivalent is usually less for dried flower than processed cannabis products, but the introduction of dried flower would likely cause statewide cannabis retail sales to spike sharply. The introduction of dried flower sales and/or wholesaling of medical cannabis would likely be very positive for Liberty, which has a smaller retail footprint than the three largest cannabis retailers Trulieve (CSE: Curaleaf (CSE: CURA, NR) but is in the midst of ramping up its 13,000 kg/year cultivation/processing facility near Gainesville.”
Atkinson has an average return of 19.5% when recommending Liberty Health Sciences Inc.
According to TipRanks.com, Atkinson is ranked #282 out of 5144 analysts.
Read also: Spooked Investors Send ResMed (RMD) Stock Spiraling; Analysts Weigh In
Liberty Health Sciences Inc has an analyst consensus of Moderate Buy, with a price target consensus of C$1.88.
Liberty Health Sciences, Inc. engages in the production and distribution of medical cannabis through its wholly-owned subsidiary DFMMJ LLC. The company was founded on November 9, 2011 and is headquartered in Vancouver, Canada.
